A DIA ‐ MS ‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients
Molecular Oncology · 2025-09 · 19 (9) · 2686-2699
DOI: 10.1002/1878-0261.70068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 15.06.2025. Verfasst von Anne Clavreul und 11 weiteren Autor:innen. Beteiligte Einrichtung: Département de Neurochirurgie, CHU d'Angers, France. Hauptthemen laut MEDLINE: Glioblastoma, Biomarkers, Tumor, Proteomics, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association en avant la vie.
Abstract (Originalsprache)
No blood‐based protein biomarkers are currently available for routine clinical use to determine the prognosis of patients with glioblastoma (GB). We performed data‐independent acquisition mass spectrometry (DIA‐MS)‐based proteomics on 96 presurgical serum samples from patients with GB and 30 serum samples from healthy controls to identify such markers. Among the 622 serum proteins differentially expressed between the GB and control groups, 191 had a |log 2 (fold change)| ≥ 0.58 and an area under the curve ≥ 0.75. An analysis of their prognostic value revealed that high levels of IL1R2 and low levels of CRTAC1 and HRG were associated with poor survival. Multivariate Cox regression analysis identified IL1R2 as an independent prognostic factor for PFS and CRTAC1 as an independent prognostic factor for OS. The concentration of CRTAC1 in serum samples from an independent cohort of short‐ and long‐term survivors of GB (STS and LTS, respectively) by ELISA was shown to be lower in the STS than in the LTS group. CRTAC1, HRG, and IL1R2 could potentially be used to better inform prognosis and predict treatment response in GB patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Département de Neurochirurgie, CHU d'Angers, France.
- Nantes Université, Univ Angers, INSERM, CNRS, CRCI2NA, France.
- Prot'ICO Proteomics Facility, Institut de Cancérologie de l'Ouest (ICO), Angers, France.
- Centre de Ressources Biologiques, BB-0033-00038, CHU d'Angers, France.
- Omics Data Science Unit, Institut de Cancérologie de l'Ouest (ICO), Nantes, France.
- SIRIC ILIAD, Institut de Recherche en Santé, Université de Nantes, France.
ORCID-Profile: Anne Clavreul
Förderung
- Association en avant la vie
Zitieren
APA
Clavreul, A., Guillonneau, F., Blanchet, O., Lasla, H., Rousseau, A., Guette, C., Boissard, A., Henry, C., Dhondt, M., Jézéquel, P., Menei, P., & Lemée, J. M. (2025). A DIA ‐ MS ‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients. Molecular Oncology, 19(9), 2686-2699. https://doi.org/10.1002/1878-0261.70068
Vancouver
Clavreul A, Guillonneau F, Blanchet O, Lasla H, Rousseau A, Guette C, et al. A DIA ‐ MS ‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients. Molecular Oncology. 2025;19(9):2686-2699. doi:10.1002/1878-0261.70068
BibTeX
@article{Clavreul2025,
author = {Clavreul, Anne and Guillonneau, François and Blanchet, Odile and Lasla, Hamza and Rousseau, Audrey and Guette, Catherine and Boissard, Alice and Henry, Cécile and Dhondt, Morgan and Jézéquel, Pascal and Menei, Philippe and Lemée, Jean-Michel},
title = {A DIA ‐ MS ‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients},
journal = {Molecular Oncology},
year = {2025},
volume = {19},
number = {9},
pages = {2686--2699},
doi = {10.1002/1878-0261.70068}
}
EUVIMED